title: Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
abstract: Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.
authors: Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom. Electronic address: rury.holman@dtu.ox.ac.uk.
authors: Rury R
authors: RR
authors: Holman
authors: Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
authors: Mary A
authors: MA
authors: Bethel
authors: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
authors: Juliana C N
authors: JC
authors: Chan
authors: CRCHUM, Department of Medicine, University of Montreal, Montreal, Canada.
authors: Jean-Louis
authors: JL
authors: Chiasson
authors: Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
authors: Zoë
authors: Z
authors: Doran
authors: Zhongshan Hospital, Fudan University, Shanghai, China.
authors: Junbo
authors: J
authors: Ge
authors: Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
authors: Hertzel
authors: H
authors: Gerstein
authors: Department of Cardiology, Peking University First Hospital, Beijing, China.
authors: Yong
authors: Y
authors: Huo
authors: Institute of Cardiovascular & Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
authors: John J
authors: JJ
authors: McMurray
authors: Cardiology Unit, Karolinska University Hospital Solna, Stockholm, Sweden.
authors: Lars
authors: L
authors: Ryden
authors: Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
authors: Winitha
authors: W
authors: Liyanage
authors: Bayer Healthcare, Bayer Pharma AG, Berlin, Germany.
authors: Stefan
authors: S
authors: Schröder
authors: 3rd Division of Cardiology, Medical University of Silesia, Katowice, Poland.
authors: Michal
authors: M
authors: Tendera
authors: Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
authors: Michael J
authors: MJ
authors: Theodorakis
authors: Centre for Vascular Prevention, Danube-University Krems, Krems, Austria; Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland; King Abdulaziz University, Jeddah, Saudi Arabia.
authors: Jaakko
authors: J
authors: Tuomilehto
authors: China-Japan Friendship Hospital, Beijing, China.
authors: Wenying
authors: W
authors: Yang
authors: People's Hospital of Peking University, Beijing, China.
authors: Dayi
authors: D
authors: Hu
authors: Department of Endocrinology, People's Liberation Army General Hospital, Beijing, China.
authors: Changyu
authors: C
authors: Pan
mesh_terms: D020909:Acarbose / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D018450:Disease Progression; D004311:Double-Blind Method; D005500:Follow-Up Studies; D018149:Glucose Intolerance / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D011446:Prospective Studies; D055502:Secondary Prevention / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D020909:Acarbose